Menu
Search
|

Menu

Close
X

Aclaris Therapeutics Inc ACRS.OQ (NASDAQ Stock Exchange Global Select Market)

1.99 USD
-0.11 (-5.24%)
As of Jul 19
Previous Close 2.10
Open 2.09
Volume 88,313
3m Avg Volume 191,492
Today’s High 2.10
Today’s Low 1.98
52 Week High 20.75
52 Week Low 1.93
Shares Outstanding (mil) 41.27
Market Capitalization (mil) 82.13
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY19
5
FY18
10
FY17
2
FY16
0
EPS (USD)
FY19
-0.911
FY18
-4.037
FY17
-2.473
FY16
-2.259
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.52
Price to Sales (TTM)
vs sector
5.86
7.97
Price to Book (MRQ)
vs sector
0.45
4.45
Price to Cash Flow (TTM)
vs sector
--
24.33
Total Debt to Equity (MRQ)
vs sector
16.89
17.60
LT Debt to Equity (MRQ)
vs sector
16.42
12.58
Return on Investment (TTM)
vs sector
-66.11
12.69
Return on Equity (TTM)
vs sector
-73.20
17.17

EXECUTIVE LEADERSHIP

Neal Walker
President, Chief Executive Officer, Director, Since 2012
Salary: $550,000.00
Bonus: --
Frank Ruffo
Co-Founder, Chief Financial Officer, Since 2016
Salary: --
Bonus: --
Stuart Shanler
Chief Scientific Officer, Since 2012
Salary: $400,000.00
Bonus: --
Kamil Ali-Jackson
Chief Legal Officer, Chief Compliance Officer, Secretary, Since 2016
Salary: $320,000.00
Bonus: --
David Gordon
Chief Medical Officer, Since 2018
Salary: $244,444.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

640 Lee Rd Ste 200
WAYNE   PA   19087-5636

Phone: +1484.3247933

Aclaris Therapeutics, Inc. is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer. The Company’s drug discovery platform KINect technology is a kinase-focused drug discovery engine utilizing computational chemistry to integrate proprietary compound collections and highly experienced biologists and medicinal chemists to identify and advance potential candidates into preclinical and clinical development.

SPONSORED STORIES